Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Genitourinary tumours, non-prostate

703MO - An integrated study of spatial dynamics and genomic alterations in renal cell carcinoma evolution


18 Sep 2020


Mini Oral - Genitourinary tumours, non-prostate


Tumour Site

Renal Cell Cancer


Yue Zhao


Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274


Y. Zhao1, A. Rowan2, J.I. Lopez3, C. Swanton4, S. Turajlic5, K.R. Litchfield6

Author affiliations

  • 1 Cancer Evolution And Genome Instability Laboratory, Francis Crick Institute, NW1 1AT - London/GB
  • 2 Cancer Evolution And Genome Instability Laboratory, The Francis Crick Institute, NW1 1AT - London/GB
  • 3 Department Of Pathology, Cruces University Hospital, 48903 - Barakaldo/ES
  • 4 Cancer Research Uk Lung Cancer Centre Of Excellence, Cancer Evolution And Genome Instability Laboratory, University College London and The Francis Crick Institute, NW1 1AT - London/GB
  • 5 Renal And Skin Units, The Royal Marsden Hospital - NHS Foundation Trust, SW3 6JJ - London/GB
  • 6 Swanton Lab, Francis Crick Institute, NW1 1AT - London/GB


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 703MO


The multi-center prospective longitudinal cohort study, TRACERx Renal (NCT03226886) has revealed the evolutionary features of clear-cell renal cell carcinoma (ccRCC). However, the association of physical spatial location and genetically driven tumour subclones was unclear.


100 macroscopic tumour images taken at time of surgery were reviewed by a renal pathologist, and following quality control filtering accurate spatial data was available for 79 tumours. From these 79 cases, matched high-depth driver gene panel sequencing data was utilised from 756 individual biopsy regions (mean 9.6 biopsies per tumour). The boundaries between tumour and normal tissues were marked based on macroscopic photos by a renal pathologist, after which the positions of boundaries and biopsy regions were digitally extracted to X- and Y-coordinates. Spatial distances were calculated, with the correlations between spatial characteristics and genomic alterations investigated.


We mapped the spatial location of 756 biopsies, across 79 ccRCCs, and integrated these coordinates with sequencing data. This enabled a resolution as to how genetically distinct subclones grow and evolve spatially. Compared with tumour margins, the level of somatic copy number changes was higher in tumour interiors. Moreover, metastasising clones were found to be more enriched in tumour interiors. The tumour subclones growing to largest physical size were characterised by gains of chromosomes 7q, 1q and and losses of chromosome 14q. The degree of discrepancy of genomic alterations across biopsy regions was positively correlated with spatial distances across biopsy regions. Tumour subclone growth was found to be predominantly spatially contiguous, with subclone dispersal a rare event found only in one case, which notably was associated with metastasis.


Spatial dynamics is strongly associated with genomic alterations and plays an important role in tumour evolution.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Royal Marsden Hospital.


UK Medical Research Council, the Rosetrees Trust, Cancer Research UK, UK Medical Research Council, the Wellcome Trust, the European Research Council, the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden Hospital, Institute of Cancer Research, the Kidney and Melanoma Cancer Fund of The Royal Marsden Cancer Charity, Ventana Medical Systems Inc.


C. Swanton: Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): BMS; Advisory/Consultancy, Research grant/Funding (institution): Roche-Ventana; Research grant/Funding (institution): Boehringer-Ingelheim; Research grant/Funding (institution): Ono; Advisory/Consultancy: Novartis; Advisory/Consultancy: GlaxoSmithKline; Advisory/Consultancy: MSD; Advisory/Consultancy: Illumina; Advisory/Consultancy: Genentech; Advisory/Consultancy, Shareholder/Stockholder/Stock options: GRAIL; Advisory/Consultancy: Medicxi; Advisory/Consultancy: Celgene; Advisory/Consultancy: Sarah Cannon Research Institute; Shareholder/Stockholder/Stock options: Apogen Biotechnologies; Shareholder/Stockholder/Stock options: Epic Bioscience; Shareholder/Stockholder/Stock options, Co-founder: Achilles Therapeutics. S. Turajlic: Research grant/Funding (institution): Roche Tissue Dianostics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.